Tag: antiplatelet

1. Clopidogrel monotherapy reduced long-term rates of all-cause mortality, non-fatal myocardial infarction, and stroke after drug-eluting stent placement compared with aspirin monotherapy. 2. The superiority of clopidogrel was seen for both thrombotic and bleeding endpoints and was consistent across demographic groups. Evidence Rating Level: 1 (Excellent)  Study Rundown: Patients who receive percutaneous...

1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy. 2. Guided selection strategy was beneficial for both escalation and de-escalation of standard therapy, balancing patient-dependent ischemic and bleeding risks.  Evidence Rating Level: 1 (Excellent) Study Rundown: Patients who undergo percutaneous coronary intervention (PCI)...

1. The incidence of having reduced antiplatelet activity to aspirin (ALR) increased after vascular procedures. Evidence Rating Level: 1 (Excellent) Though clinical guidelines often recommend antiplatelet therapy in secondary and tertiary prevention of thromboembolic events, studies investigating their efficacy have shown variable results. Moreover, while vascular surgery patients are at high...

1. There was no significant difference in periprocedural myonecrosis between ticagrelor and clopidogrel among patients undergoing high-risk elective PCI. 2. Ticagrelor treatment was associated with an increased rate of minor bleeding at 30 days post-operation. Evidence Rating Level: 1 (Excellent) Study Rundown: Percutaneous coronary intervention (PCI) provides a safe therapeutic option for...

1. There does not appear to be any difference in outcome between pre- and post-treatment administration of P2Y12 inhibitors among patients experiencing a non-ST elevation acute coronary syndrome with planned invasive intervention. 2. Prasugrel and ticagrelor showed similar outcomes when administered post-treatment. Evidence Rating Level: 1 (Excellent) Though it is well established...

1. After successful transcatheter aortic valve replacement, compared to an anti-platelet based strategy, patients that received an anti-coagulation strategy including rivaroxaban at a dose of 10 mg daily had a higher risk of death, thromboembolic complications, and bleeding. Evidence Rating: 1 (Excellent) Transcatheter aortic-valve replacement (TAVR) is a treatment option for patients...

Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial 1. Bleeding after percutaneous coronary intervention (PCI) was more common in women, but the effect of two antiplatelet strategies on death and new Q-wave myocardial infarction following PCI did...

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial While dual antiplatelet therapy (DAPT) is the standard of care post-percutaneous coronary intervention (PCI) using drug-eluting stents (DES), the optimal duration of...

Patients with a history of occlusive vascular disease who are on antithrombotic therapy are at an increased risk of intracerebral hemorrhage. Generally, antithrombotic therapy is discontinued after intracerebral hemorrhage in these patients. However, no published randomized trials have studied the long-term safety of antithrombotic therapy in survivors of intracerebral...

Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study Venous thromboembolism (VTE) is a common complication in patients with cancer. Often, VTEs are incidentally detected on imaging studies undertaken for cancer staging or evaluation of treatment response. Current guidelines recommend that...